Video

Q&A With Jay Edelberg From Sanofi: Answering More Questions Since PCSK9 Approval

Author(s):

It was not that long ago that PCSK9 inhibitors were just an idea being discussed in the field of cardiology. Just a few months ago the FDA approved the first treatments which has meant answers to many questions with some questions still remaining.

It was not that long ago that PCSK9 inhibitors were just an idea being discussed in the field of cardiology. Just a few months ago the FDA approved the first treatments which has meant answers to many questions with some questions still remaining.

Jay Edelberg, MD, PhD, from Sanofi discussed how far the field has come in recent years, what it has meant to patient care so far, and what work remains to be done during the annual scientific sessions of the American Heart Association in Orlando.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Viet Le, DMSc, PA-C | Credit: APAC
Marianna Fontana, MD, PhD: Declines in Kidney Function Frequent in ATTR-CM  | Image Credit: Radcliffe Cardiology
© 2024 MJH Life Sciences

All rights reserved.